Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OptiHER-Heart: Neoadjuvant Myocet, Paclitaxel, Trastuzumab, and Pertuzumab in HER2+ Breast Cancer
NCT01669239Phase 2Completed
- Sponsor
- SOLTI
- Start
- Jun 2013
- Primary completion
- Jan 2016
- Countries
- 1
01
Overview
A Phase 2 trial of doxorubicin in breast cancer, sponsored by SOLTI. Started Jun 2013; status: completed.
02
Drugs
doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01669239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01669239.